Looking Ahead: Visual and Anatomical Endpoints in Future Trials of Diabetic Macular Ischemia.

ABSTRACT: Diabetic macular ischemia (DMI) is a common complication of diabetic retinopathy that can lead to progressive and irreversible visual loss. Despite substantial clinical burden, there are no treatments for DMI, no validated clinical trial endpoints, and few clinical trials focusing on DMI. Therefore, generating consensus on validated endpoints that can be used in DMI for the development of effective interventions is vital. In this review, we discuss potential endpoints appropriate for use in clinical trials of DMI, and consider the data required to establish acceptable and meaningful endpoints. A combination of anatomical, functional, and patient-reported outcome measures will provide the most complete picture of changes that occur during the progression of DMI. Potential endpoint measures

SUBMITTER: Cheung CMG 

PROVIDER: S-EPMC8619758 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature